Yersinia outer proteins (YOPS) E, K and N are antigenic but non-protective compared to V antigen, in a murine model of bubonic plague

Microbial Pathogenesis

Volumn 26, Issue 3, 1999, Pages 159-169

  Leary, Sophie E C ^a   Griffin, Kate F ^a   Galyov, Edouard E ^c,d   Hewer, Jason ^a   Williamson, E Diane ^a   Holmström, Anna ^b   Forsberg, Åke ^b   Titball, Richard W ^a  

^a DEFENCE SCIENCE AND TECHNOLOGY LABORATORY   (United Kingdom)

^b SWEDISH DEFENCE RESEARCH AGENCY   (Sweden)

^c UMEÅ UNIVERSITY   (Sweden)

^d INSTITUTE FOR ANIMAL HEALTH   (United Kingdom)

Author keywords

Interleukin 12; LcrV; Plague; V antigen; Yersinia; Yops

Indexed keywords

ALUMINUM HYDROXIDE; BACTERIAL ANTIGEN; BACTERIAL VACCINE; IMMUNOGLOBULIN G ANTIBODY; INTERLEUKIN 12; OUTER MEMBRANE PROTEIN; VIRULENCE FACTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ANTIGENICITY; ARTICLE; BACTERIAL IMMUNITY; CONTROLLED STUDY; FEMALE; IMMUNIZATION; INTRAPERITONEAL DRUG ADMINISTRATION; MOUSE; NONHUMAN; PLAGUE; PRIORITY JOURNAL; YERSINIA PESTIS;

ANIMALIA; BACTERIA (MICROORGANISMS); MURINAE; NEGIBACTERIA; YERSINIA; YERSINIA PESTIS;

EID: 0033103401     PISSN: 08824010     EISSN: None     Source Type: Journal    
DOI: 10.1006/mpat.1998.0261     Document Type: Article

References (59)

1. Russell P, Eley SM, Hibbs SE, Manchee RJ, Stagg AJ, Titball RW. A comparison of plague vaccine, USP and EV76 vaccine induced protection against Yersinia pestis in a murine model. Vaccine 1995; 13: 1551-6.
2. Williamson ED, Eley SM, Stagg AJ, Green M, Russell P, Titball RW. A sub-unit vaccine elicits IgG in serum, spleen cell cultures and bronchial washings and protects immunised animals against pneumonic plague. Vaccine 1997; 15: 1079-84.
3. Meyer KF. Effectiveness of live or killed plague vaccines in man. Bull WHO 1970; 42: 653-66.
4. Leary SEC, Williamson ED, Griffin KF, Russell P, Eley SM, Titball RW. Active immunisation with recombinant V antigen from Yersinia pestis protects mice against plague. Infect Immun 1995; 63: 2854-8.
5. Nakajima R, Motin VL, Brubaker RR. Suppression of cytokines in mice by protein A-V antigen fusion peptide and restoration of synthesis by active immunisation. Infect Immun 1995; 63: 3021-9.
6. Anderson Jr GW, Leary SEC, Williamson ED, et al. Recombinant V antigen protects mice against pneumonic and bubonic plague caused by F1-capsule positive and -negative strains of Yersinia pestis. Infect Immun, 1996; 64: 4580-5.
7. Nemeth J, Straley SC. Effect of Yersinia pestis YopM on experimental plague. Infect Immun 1997; 65: 924-30.
8. Andrews GP, Heath DG, Anderson Jr GW, Welkos SL, Friedlander AM. Fraction 1 capsular antigen (F1) purification from Yersinia pestis CO92 and from an Escherichia coli recombinant strain and efficacy against lethal plague challenge. Infect Immun 1996; 64: 2180-7.
9. Williamson ED, Eley SM, Griffin KF et al. A new improved subunit vaccine for plague: The basis of protection. FEMS Immunol Med Microbiol 1995; 12: 223-30.
10. Heath DG, Anderson Jr GW, Mauro JM et al. Protection against experimental plague by a recombinant capsular F1-V antigen fusion protein vaccine. Vaccine 1998; 16: 1131-7.
11. Friedlander AM, Welkos SL, Worsham PL, et al. Relationship between virulence and immunity as revealed in recent studies of the F1 capsule of Yersinia pestis, Clin Infect Dis 1995; 21 (Suppl 2): S178-81.
12. Roggenkamp A, Geiger A, Leitritz L, Kessler A, Heesemann J. Passive immunity to infection with Yersinia spp. mediated by anti-recombinant V antigen is dependent on polymorphism of V antigen. Infect Immun 1997; 65: 446-51.
13. Perry RD, Fetherston JD. Yersinia pestis - etiologic agent of plague. Clin Microbiol Rev 1997; 10: 35-66.
14. Cornelis GR, Wolf-Watz H. The Yersinia Yop virulon: A bacterial system for subverting eukaryotic cells. Mol Microbiol 1997; 23: 861-7.
15. Martinez RJ. Plasmid-mediated and temperature-regulated surface properties of Yersinia enterocolitica. Infect Immun 1983; 41: 921-30.
16. Bölin I, Portnoy DA, Wolf-Watz H. Expression of the temperature-inducible outer membrane proteins of Yersiniae. Infect Immun 1985; 48: 234-40
17. Mazza G, Karu AE, Kingsbury DT. Immune responses to plasmid- and chromosome-encoded Yersinia antigens. Infect Immun 1985; 48: 676-85.
18. Ståhlberg TH, Tertti R, Wolf-Watz H, Granfors K, Toivanen A. Antibody response in Yersinia pseudotuberculosis III infection: Analysis of an outbreak. J Infect Dis 1987; 156: 388-91.
19. Benner GE, Andrews GP, Byrne WR, Heath DG, Friedlander AM. The immune responses to Yersinia outer proteins and other virulence determinants after experimental plague infection in mice. In: Abstracts of 97th General Meeting of the American Society for Microbiology. Washington, DC: ASM Press, 1997; 96.
20. Rosqvist R, Magnusson K-E, Wolf-Watz H. Target cell contact triggers expression and polarised transfer of Yersinia YopE cytotoxin into mammalian cells. EMBO J 1994; 13: 964-72.
21. Sory M.-P, Cornelis GR. Translocation of a hybrid YopE-adenylate cyclase from Yersinia enterocolitica into HeLa cells. Mol Microbiol 1994; 14: 583-94.
22. Persson C, Nordfelth R, Holmström A, Håkansson S, Rosqvist R, Wolf-Watz H. Cell surface bound Yersinia translocate the protein tyrosine phosphatase YopH by a polarised mechanism into the target cell. Mol Microbiol 1995; 18: 135-50.
23. Boland A, Sory M-P, Iriarte M, Kerbouch C Wattiau P, Cornelis, GR. Status of YopM and YopN in the Yersinia Yop virulon: YopM of Y. enterocolitica is internalised inside the cytosol of PU5-1.8 macrophages by the YopB, D,N delivery apparatus. EMBO J 1996; 15: 5191-201.
24. Håkansson S, Galyov E, Rosqvist R, Wolf-Watz H. The Yersinia YpkA Ser/Thr kinase is targeted to the inner surface of the HeLa cell plasma membrane by a YopB-dependent mechanism. Mol Microbiol 1996; 20: 593-603.
25. Mills SD, Boland A, Sory M-P, et al. Yersinia enterocolitica induces apoptosis in macrophages by a process requiring functional type III secretion and translocation mechanisms and involving YopP, presumably acting as an effector protein. Proc Natl Acad Sci 1997; 94: 12638-43.
26. Schesser K, Spiik A, Dukuzumuremyi J-M, Neurath M, Pettersson S, Wolf-Watz H. The YopJ locus is required for Yersinia-mediated inhibition of NF-kB activation and cytokine expression: YopJ contains a eukaryotic SH2-like domain that is essential for its repressive activity. Mol Microbiol 1998; 28: 1067-79.
27. Palmer LE, Hobbie S, Galan JE, Bliska JB. YopJ of Yersinia pseudotuberculosis is required for the inhibition of macrophage TNF-α production and downregulation of the MAP kinases p38 and JNK. Mol Microbiol 1998; 27: 953-65.
28. Iriarte M, Comelis GR. YopT, a new Yersinia Yop effector protein, affects the cytoskeleton of host cells. Mol Microbiol 1998; 29: 915-29.
29. Bergman T, Håkansson S, Forsberg Å, et al. Analysis of the V antigen IcrGVH-yopBD operon of Yersinia pseudotuberculosis: Evidence for a regulatory role of LcrH and LcrV. J Bacteriol 1991; 173: 1607-16.
30. 2+ response virulence genes. J Bacteriol 1991; 173: 2649-57.
31. Sarker MR, Neyt C, Stainier I, Cornelis GR. The Yersinia pestis Yop virulon: LcrV is required for extrusion of the translocators YopB and YopD. J Bacteriol 1998; 180: 1207-14.
32. Niiles ML, Fields KA, Straley SC. The V antigen of Yersinia pestis regulates Yop vectorial targeting as well as Yop secretion through effects on YopB and LcrG. J Bacteriol 1998; 180: 3410-20.
33. Pettersson J, Holmström A, Hill J, et al. A cell surface organelle involved in virulence protein translocation contains the V antigen of Yersinia. Mol Microbiol, submitted.
34. Nedialkov YA, Motin VL, Brubaker RR. Resistance to lipopolysaccharide mediated by the Yersinia pestis V antigen-polyhistidine fusion peptide: Amplification of interleukin-10. Infect Immun 1997; 65: 1196-203.
35. WelkoS S, Friedlander A, McDowell D, Weeks J, Tobery S. V antigen Of Yersinia Pestis inhibits neutrophil chemotaxis. Microb Pathog: 1998; 24: 185-96.
36. Forsberg Å, Vitanen A-M, Skurnik M, Wolf-Watz H. The surface-located YopN protein is involved in calcium signal transduction in Yersinia pseudotuberculosis. Mol Microbiol 1991; 5: 977-86.
37. Holmström A, Pettersson J, Rosqvist R, et al. YopK of Yersinia pseudotuberculosis controls translocation of Yop effectors across the eukaryotic cell membrane. Mol Microbiol 1997; 24: 73-91.
38. Håkansson S, Persson C, Schesser K, Galyov EE, Rosqvist R, Wolf-Watz H. The YopB protein of Yersinia pseudotuberculosis is essential for translocation of Yop effector proteins across the target cell plasma membrane and displays contact-dependent membrane-disrupting activity. EMBO J 1996; 15: 5812-23.
39. Rosqvist R, Forsberg Å, Wolf-Watz H. Microinjection of Yersinia YopE cytotoxin in mammalian cells induces actin microfilament disruption. Biochem Soc Transactions 1991; 19: 1131-2.
40. Andrews GP, Howe GB, Debelak JT, Anderson Jr GW, Welkos SL, Friedlander, AM. Immunogenicity and protective efficacy of recombinant YopD, E and H from Y. pestis strain CO92. In: Abstracts of 96th General Meeting of American Society for Microbiology. Washington, DC: ASM Press, 1996; 203.
41. Gupta RK, Siber GR. Adjuvants for human vaccines - current status, problems and future prospects. Vaccine 1995; 13: 1263-76.
42. Snapper CM, Paul WE. Interferon-γ and B cell stimulatory factor-1 reciprocally regulate 1g isotype production. Science 1987; 236: 944-7.
43. Allison AC, Byars NE. An adjuvant formulation that selectively elicits the formation of antibodies of protective isotypes and of cell-mediated immunity. J Immunol Methods 1986; 95: 157-68.
44. Karagouni EE, Hadjipetrou-Kourounakis L. Regulation of isotype immunoglobulin production by adjuvants in vivo. Scand J Immunol 1990; 31: 745-54.
45. Mosmann TR, Sad S. The expanding universe of T-cell subsets: Th1, Th2 and more. Immunol Today 1996; 17: 138-46.
46. Trinchieri G. Interleukin-12: A preinflammatory cytokine with immunoregulatory functions that bridge innate resistance and antigen-specific adaptive immunity. Ann Rev Immunol 1995; 13: 251-76.
47. Afonso LCC, Scharton TM, Vieira LQ, Wysocka M, Trinchieri G, Scott P. The adjuvant effect of interleukin-12 in a vaccine against Leishmanja major. Science 1994; 263: 235-7.
48. Noll A, Autenrieth IB. Immunity against Yersinia enterocolitica by vaccination with Yersinia HSP60 immunostimulating complexes or Yersinia HSP60 plus interleukin-12. Infect Immun 1996; 64: 2955-61.
49. Motin VL, Nedialkov YA, Brubaker RR. V antigen polyhistidine fusion peptide: Binding to LcrH and active immunity against plague. Infect Immun 1996; 64: 4313-18.
50. Carr S, Miller J, Leary SEC, Bennett AM, Ho A, Williamson ED. A comparison of three different expression systems to produce a recombinant form of the V antigen of Yersinia pestis. Vaccine, in press.
51. Lawton WD, Erdman RL, Surgalla MJ. Biosynthesis and purification of V and W antigen in Pasteurella pestis. J Immunol 1963; 91: 179-84.
52. Motin VL, Nakajima R, Smirnov GB, Brubaker RR. Passive immunity to yersiniae mediated by anti-recombinant V antigen and protein A-V antigen fusion peptide. Infect Immun 1994; 62: 4192-201.
53. Hill J, Leary SEC, Griffin K, Williamson ED, Titball RW. Regions of Yersinia pestis V antigen that contribute to protection against plague identified by passive and active immunisation. Infect Immun 1997; 65: 4476-82.
54. Fällman M, Andersson K, Håkansson S, Magnusson K-E, Stendahl O, Wolf-Watz H. Yersinia pseudotuberculosis inhibits Fc receptor-mediated phagocytosis in J774 cells. Infect Immun 1995; 63: 3117-24.
55. Brubaker RR. Factors promoting acute and chronic diseases caused by Yersiniae. Clin Microbiol Rev 1991; 4: 309-24.
56. Holmström A, Rosqvist R, Wolf-Watz H, Forsberg Å. Virulence plasmid-encoded YopK is essential for Yersinia pseudotuberculosis to cause systemic infection in mice. Infect Immun 1995; 63: 2269-276.
57. Rosqvist R, Håkansson S, Forsberg Å, Wolf-Watz H. Functional conservation of the secretion and translocation machinery for virulence proteins of Yersiniae, salmonellae and shigellae. EMBO J 1995; 14: 4187-95.
58. Forsberg Å, Bölin I, Norlander L, Wolf-Watz H. Molecular cloning and expression of calcium-regulated, plasmid-coded proteins of Y. pseudotuberculosis. Microb Pathog 1987; 2: 123-137.
59. Mahon BP, Ryan MS, Griffin F, Mills KHG. Interleukin-12 is produced by macrophages in response to live or killed Bordetella pertussis and enhances the efficacy of an acellular pertussis vaccine by promoting induction of Th1 cells. Infect Immun 1996; 64: 5295-301.